Home > References > Safety of inactivated influenza vaccines

Safety of inactivated influenza vaccines: References

1.        Medsafe. Data sheet – Fluad Quad [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2020 [updated 2020 December 11; cited 2021 February 3]. Available from: https://www.medsafe.govt.nz/profs/ Datasheet/f/FluadQuadinj.pdf

2.        Medsafe. Data sheet – Afluria Quad/Afluria Quad Junior [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2017 [updated 2021 March 12; cited 2021 March 30]. Available from: https://www.medsafe.govt.nz/profs/ Datasheet/a/Afluriainj.pdf

3.        Medsafe. Data sheet – FluQuadri [Internet] Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2022 [updated 2022 January 26; cited 2022 February 15]. Available from: https://www.medsafe.govt.nz/profs/datasheet/f/ fluquadriinj.pdf

4.        Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59™ adjuvant. Vaccine. 2008;26(26):3209-22.

5.      Feng S, Fowlkes AL, Steffens A, Finelli L, Cowling BJ. Assessment of virus interference in a test-negative Study of influenza vaccine effectiveness. Epidemiology. 2017;28(4):514-24.

6.        Skowronski DM, Zou M, Clarke Q, Chambers C, Dickinson JA, Sabaiduc S, et al. Influenza vaccine does not increase the risk of coronavirus or other noninfluenza respiratory viruses: Retrospective analysis from Canada, 2010–2011 to 2016–2017. Clin Infect Dis. 2020;71(16):2285-8.

7.        Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092-102.

8.        Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017;35(15):1856-64.

9.        Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine. 2017;35(20):2745-52.

10.      Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6–59 months of age: A phase 3, randomized, noninferiority study. Vaccine. 2019;37(2):343-51.

11.      Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65.

12.      Frey SE, Reyes MRA-DL, Reynales H, Bermal NN, Nicolay U, Narasimhan V, et al. Comparison of the safety and immunogenicity of an MF59®- adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-34.

13.      Cowling BJ, Thompson MG, Ng TWY, Fang VJ, Perera RAPM, Leung NHL, et al. Comparative reactogenicity of enhanced influenza vaccines in older adults. J Infect Dis. 2020;222(8):1383-91.

14.      Nicolay U, Heijnen E, Nacci P, Patriarca PA, Leav B. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019;85:S1-S9.

15.      McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-78.

16.      Bresee J, Fry A, Sambhara S, Cos N. Inactivated influenza vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 456-88.

17.      Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.

18.      Sawlwin DC, Graves Jones A, Albano FR. Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children. Vaccine. 2019;37(18):2447

19.     McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barre syndrome worldwide. Neuroepidemiology. 2009;32(2):150- 63.

20.     Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, Ziegler D, Retailliau H, et al. Guillain- Barre syndrome following vaccination in the National Influenza Program, United States, 1976– 1977. Am J Epidemiol. 1979;110(2):105-23.

21.   Arias LHM, Sanz R, Sainz M, Treceno C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015;33(31):3773-8.

22.    Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barre syndrome, influenza-related hospitalizations, and influenza vaccine coverage. Vaccine. 2015;33(17):2045-9.

23.     Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169(3):382-8

24.     Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barre syndrome: Making informed decisions. Lancet. 2013;381(9876):1437- 9.

25.    Sadleir LG, Scheffer IE. Febrile seizures. BMJ. 2007;334(7588):307-11

26.  Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatrics. 2014;168(3):211-9.